Patient Adherence for Oral Combination Therapies in Diabetes Management: A Scoping Review
Abstract
Background and aims: Diabetes imposes a global healthcare burden, with Type 2 Diabetes Mellitus (T2DM) escalating due to demographic shifts and lifestyle changes. Combination therapies offer promise in managing T2DM, yet patient adherence remains a challenge. This scoping review aims to explore patient adherence to combination therapies in T2DM management.
Materials and methods: This scoping review followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews guidelines. Electronic databases including PubMed, Scopus, and Web of Science were searched until July 10, 2024. Studies focused on patients with T2DM prescribed oral combination therapies were included. Data extraction and synthesis were conducted to identify adherence patterns, influencers, and strategies.
Results: The review identified nine eligible studies spanning from 2004 to 2021, primarily retrospective cohort and cross-sectional designs. Adherence assessment methods varied, with medication possession ratio being the most common. Both dual (loose-dose) and fixed-dose combination therapies were explored. Adherence rates varied across studies and therapies, influenced by factors such as glycemic control, weight management, economic considerations, complexity of regimens, and demographic factors. Bibliometric analysis revealed diverse geographic origins of the included studies and varied adherence assessment methods. Dual therapy regimens demonstrated adherence rates…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.